RBM3 and breast cancer: Taken together, these data demonstrate that RBM3 is a marker of good prognosis in EOC and a predictor of response to platinum-based chemotherapy, most likely a combination of both, particularly in the light of the previously demonstrated good prognosis associated with RBM3 expression in breast cancer patients, where the vast majority of patients received no adjuvant systemic chemotherapy [16].